5-alpha Reductase Inhibitors
"5-alpha Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
| Descriptor ID |
D058891
|
| MeSH Number(s) |
D27.505.519.389.870.200 D27.505.696.399.450.855.200
|
| Concept/Terms |
5-alpha Reductase Inhibitors- 5-alpha Reductase Inhibitors
- 5 alpha Reductase Inhibitors
- Inhibitors, 5-alpha Reductase
- Reductase Inhibitors, 5-alpha
- Steroid 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Steroid
- Inhibitors, Steroid 5-alpha-Reductase
- Steroid 5 alpha Reductase Inhibitors
- Testosterone 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Testosterone
- Inhibitors, Testosterone 5-alpha-Reductase
- Testosterone 5 alpha Reductase Inhibitors
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitors
- 3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitors
- 4-Dehydrogenase Inhibitors, 3-Oxo-5-alpha-Steroid
- Inhibitors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
|
Below are MeSH descriptors whose meaning is more general than "5-alpha Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "5-alpha Reductase Inhibitors".
This graph shows the total number of publications written about "5-alpha Reductase Inhibitors" by people in this website by year, and whether "5-alpha Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "5-alpha Reductase Inhibitors" by people in Profiles.
-
Differential Gene Expression in Post-Finasteride Syndrome Patients. J Sex Med. 2021 09; 18(9):1479-1490.
-
In older men, 5a-reductase inhibitors were linked to increased risk for self-harm and depression but not suicide. Ann Intern Med. 2017 07 18; 167(2):JC9.
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Dig Dis Sci. 2012 Nov; 57(11):3004-10.
-
5a-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011 Dec 15; 365(24):2340.
-
Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol. 2007 Oct; 178(4 Pt 1):1521-7.
-
The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002 May; 167(5):2105-8.
-
Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab. 1995 Jun; 80(6):1934-40.
-
Effects of 4-MAPC, a 5 alpha-reductase inhibitor, and cyproterone acetate on regrowth of the rat ventral prostate. Prostate. 1994 Apr; 24(4):212-20.
-
Effects of finasteride on the rat ventral prostate. J Androl. 1993 Mar-Apr; 14(2):79-86.
-
4-MAPC, a 5 alpha-reductase inhibitor, reduces rat ventral prostate weight, DNA, and prostatein concentrations. J Androl. 1991 Sep-Oct; 12(5):315-22.